Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months

Loading news article.

Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months | WAPE

Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months

Article summary

Related companies

Comments —